BCR inhibitor failure in CLL: An unmet need

Abstract

In this issue of Blood, Mato et al report a retrospective cohort analysis of patients with chronic lymphocytic leukemia (CLL) who discontinued a kinase inhibitor (KI).1 Drug toxicity was the main reason for treatment discontinuation. Approximately 50% of patients who discontinued a KI responded to a subsequent salvage therapy.